Temozolomide

替莫唑胺

Report date: 2026/04/24 20:01:59
NME

Base Information

Drug NameTemozolomide
Drug Alias NameTemozolomidaTemozolomidum泰道Temodar蒂清 +[15
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsVaccinationBrain metastasesSkin Melanoma +[53
Global Approved IndicationsGlioblastomaAstrocytomaGlioma
Approved Indications in ChinaGlioblastoma
Original Approved Country/TerritoryEU
Original Approved Date1999/01/26
Country/TerritoryCzechiaBelgiumCanada +[26
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active IndicationsVaccinationCNS Embryonal TumorFrailty +[17
Inactive IndicationsBrain metastasesSkin MelanomaSolid tumours +[36

Other Information

ATC CodeL01AX03